GSK is top contender for $1.5 billion pneumococcal vaccine scheme
This article was originally published in Scrip
Executive Summary
GlaxoSmithKline and two Indian firms (Serum Institute of India and Panacea Biotec) have applied to supply their pneumoccoccal vaccines for children in developing countries under the $1.5 billion UNICEF /Gavi Alliance advanced market commitment (AMC) scheme, Scrip has learnt.